<?xml version="1.0" encoding="UTF-8"?>
<p>The incidence of HCV-associated glomerular disease is low and this makes it difficult to conduct clinical trials to control the disease [
 <xref rid="B3-pathogens-08-00176" ref-type="bibr">3</xref>]. Renal disease is now considered an important cause of morbidity and mortality in MC vasculitis induced by HCV [
 <xref rid="B3-pathogens-08-00176" ref-type="bibr">3</xref>]. Treatment of HCV has made considerable progress with the recent introduction of IFN-free combinations of DAAs which increased dramatically the rates of viral clearance [
 <xref rid="B3-pathogens-08-00176" ref-type="bibr">3</xref>]. The purpose of this review is to report the most important data concerning the treatment of HCV-related glomerular disease, an important extra-hepatic complication of HCV infection.
</p>
